COMPANY PROFILE

Lucy Therapeutics

Explore full profile

Innovative biotech targeting mitochondrial dysfunction to combat CNS disorders

Waltham, United StatesFounded 2017Biotech & Life Sciences

Valuation $50–100M Last recorded · 2024

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Lucy Therapeutics

Lucy Therapeutics is a biotechnology company focused on addressing central nervous system (CNS) disorders by targeting mitochondrial dysfunction. The company operates in the healthcare and biotech market, serving clients such as pharmaceutical companies, research institutions, and healthcare providers. Lucy Therapeutics employs a research-driven business model, leveraging scientific discoveries to develop therapeutic solutions. The company generates revenue through partnerships, licensing agreements, and potential future sales of its therapeutic products. By unraveling the complex processes that drive mitochondrial dysfunction, Lucy Therapeutics aims to slow or stop disease progression and restore health.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2017
Headquarters: Waltham, United States
Employees: 3
Open positions: None listed
Dealroom signal: 58.4/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VC✓Equity / VC	May 2024	$13M	$50M	Safar Partners · Parkinson's UK · Engine Ventures · Bill Gates	↗
GRANT✓Other financing	May 2024	$2M	—	Michael J. Fox Foundation for Parkinson's Research	↗

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Lucy Therapeutics website traffic

Latest recorded traffic for Lucy Therapeutics is 70 monthly website visits, down 81.6% over the last three months. Lucy Therapeutics's team declined 50% over the past year.

Latest monthly visits70 3-month web change-81.6% 1-year team growth-50%

Monthly website visitsOct 2020–Jun 2025

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
LTLTZ TherapeuticsDevelops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need	Redwood City, United States	Operational	44	$142M	$400M
DLDisruption LabsA R&D and manufacturing firm that utilizes pharmaceutical grade nano-bioengineering and applies it to consumer products	Tampa, United States	Operational
APApoGlyxDeveloping new therapeutic concepts for metabolic and inflammatory diseases with innovative and proprietary Aquaporin technology	Lund Municipality, Sweden	Operational
CECell2CureClinical-stage biotherapeutic company that uses allogeneic adipose tissue derived mesenchymal stromal cells for clinical cellular therapies	Birkerød, Denmark	Operational
KTKeapstone TherapeuticsSmall molecule activators for neurodegenerative disease therapies	Sheffield, United Kingdom	Operational
BIBiofourmisBiotechnology company that augments personalized care and therapies using digital therapeutics	Boston, United States	Operational
ALAlertgyAlertgy is on the brink of truly revolutionising the diabetes space with their non-invasive technology	Melbourne, United States	Operational
WAWaveBreakSmall-molecule therapeutics for neurodegenerative diseases	Cambridge, United Kingdom	Operational